FME Stock Chart & Stats
CHF36.28
-CHF75.28(-100.00%)
At close: 4:00 PM EDT
CHF36.28
-CHF75.28(-100.00%)
Day’s Range― - ―
52-Week RangeCHF31.91 - CHF97.00
Previous CloseN/A
Volume400.00
Average Volume (3M)0.00
Market Cap
CHF9.27B
Enterprise ValueCHF21.51B
Total Cash (Recent Filing)CHF1.45B
Total Debt (Recent Filing)CHF10.96B
Price to Earnings (P/E)11.3
Beta-0.18
Next Earnings
Nov 03, 2026EPS Estimate
0.99Next Dividend Ex-DateN/A
Dividend Yield3.87%
Share Statistics
EPS (TTM)3.32
Shares Outstanding268,564,640
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF34.81Price Target Upside-4.04% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering12
EPS Forecast (FY)3.8
Revenue Forecast (FY)CHF18.10B
Bulls Say, Bears Say
Bulls Say
Recurring Integrated DemandDialysis treatments require multiple sessions each week, while consumables are needed for each session; combining clinics with products therefore creates recurring demand across internal and external customers. This integrated base can support durable revenue visibility over the next several quarters.
Improving Operating PerformanceTTM revenue growth of 35.8% alongside EBIT margin expansion to about 10.8% from 6.8% in 2023 indicates meaningful improvement in both scale and operating efficiency. If sustained, this combination can strengthen earnings capacity and provide more resources for investment.
Solid Cash GenerationTTM operating cash flow of about 2.83B and free cash flow of 1.78B demonstrate substantial cash generation from the operating base. Consistent conversion supports ongoing investment and financial commitments, even though the latest growth rate was modestly softer.
Bears Say
Mid-level Net ProfitabilityNet margin of about 4.8% remains only mid-level and has been roughly flat versus 2025, while margins have varied across years. This leaves less earnings protection if operating conditions become less favorable over the medium term.
Reduced Equity CushionEquity has declined from 2022–2024 highs to TTM levels, reducing the balance-sheet cushion even as debt-to-equity improved to about 0.83. A smaller equity base can limit resilience and flexibility if profitability weakens or funding needs increase.
Softer Free-cash-flow MomentumFree cash flow growth was slightly negative at -3.6% in TTM after a modest increase in 2025. Although cash generation remains solid, this reversal signals softer recent momentum and could constrain the pace at which internally generated funds support expansion or distributions.
FME FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
Fresenius Medical Care AG & Co. KGaA lowest stock price was CHF31.91 and its highest was CHF97.00 in the past 12 months.
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
Fresenius Medical Care AG & Co. KGaA’s market cap is CHF9.27B.
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date is Nov 03, 2026 which is in 22 days.
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Fresenius Medical Care AG & Co. KGaA released its earnings results on Aug 03, 2026. The company reported CHF1.045 earnings per share for the quarter, beating the consensus estimate of CHF0.993 by CHF0.051.
Is Fresenius Medical Care AG & Co. KGaA overvalued?
According to Wall Street analysts Fresenius Medical Care AG & Co. KGaA’s price is currently Overvalued.
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
Fresenius Medical Care AG & Co. KGaA pays a Annually dividend of CHF1.39 which represents an annual dividend yield of 3.87%. See more information on Fresenius Medical Care AG & Co. KGaA dividends here
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
Fresenius Medical Care AG & Co. KGaA’s EPS estimate is 0.99.
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
Fresenius Medical Care AG & Co. KGaA has 268,564,640 shares outstanding.
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Fresenius Medical Care AG & Co. KGaA reported an EPS of CHF1.045 in its last earnings report, beating expectations of CHF0.993. Following the earnings report the stock price went up 1.907%.
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
Currently, no hedge funds are holding shares in CH:FME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
CHF34.81 (-4.04% Downside)
CHF34.81 (-4.04% Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.22%
12-Months-Change
Fundamentals
Return on Equity
7.21%
Trailing 12-Months
Asset Growth
<0.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
FME Stock 12 Month Forecast
Average Price Target
CHF34.81
▼(-4.04% Downside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius SE & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―











